International SARS-CoV-2 (COVID-19) Infection Observational Study

CompletedOBSERVATIONAL
Enrollment

11,973

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
COVIDCOVID19SARS-CoV 2Dyspnea
Interventions
OTHER

Data Collection

"DATA COLLECTION AT ENROLLMENT:~Demographics; Symptoms and health status; Co-morbidities; Targeted medications; Specimen Collection (substudy at selected sites): Upper respiratory swab, blood for serum storage.~DATA COLLECTION AT DAYS 7, 14 \& 28:~Vital and hospitalization status; Symptoms and health status"

Trial Locations (4)

80204

Denver Public Health, Denver

C1221ADC

Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires

Unknown

CHIP Department of Infectious Diseases, Copenhagen

WC1E

University College London Medical School Centre for Sexual Health and HIV Research, London

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Minnesota

OTHER

NCT04385251 - International SARS-CoV-2 (COVID-19) Infection Observational Study | Biotech Hunter | Biotech Hunter